Whanin Pharm (KO:016580) — Stock Price
Whanin Pharm (KO:016580) is currently trading at ₩10350.00 KRW, down 0.48% today. Over the past 52 weeks, shares have ranged between ₩9230.00 and ₩11930.00. This page tracks Whanin Pharm's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 016580 stock market capitalisation.
Whanin Pharm (016580) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Whanin Pharm's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Whanin Pharm Income Statement — Revenue, Profit & Earnings by Year
Whanin Pharm's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩255.21 Billion | ₩259.60 Billion | ₩230.39 Billion | ₩198.93 Billion | ₩177.78 Billion |
| Cost of Revenue | ₩168.12 Billion | ₩165.82 Billion | ₩131.23 Billion | ₩100.14 Billion | ₩84.28 Billion |
| Gross Profit | ₩87.10 Billion | ₩93.78 Billion | ₩99.16 Billion | ₩98.79 Billion | ₩93.49 Billion |
| Research & Development | ₩1.22 Billion | ₩771.13 Million | ₩1.07 Billion | ₩3.33 Billion | ₩2.66 Billion |
| SG&A | ₩33.74 Billion | ₩38.71 Billion | ₩36.42 Billion | ₩35.29 Billion | ₩29.08 Billion |
| Total Operating Expenses | ₩242.20 Billion | ₩238.10 Billion | ₩200.22 Billion | ₩169.12 Billion | ₩146.50 Billion |
| Operating Income | ₩13.02 Billion | ₩21.50 Billion | ₩30.17 Billion | ₩29.81 Billion | ₩31.28 Billion |
| EBITDA | — | — | — | ₩34.71 Billion | ₩38.14 Billion |
| EBIT | — | — | — | ₩29.81 Billion | ₩31.28 Billion |
| Interest Expense | ₩28.77 Million | ₩23.12 Million | ₩22.66 Million | ₩51.88 Million | ₩51.55 Million |
| Income Before Tax | ₩14.93 Billion | ₩26.95 Billion | ₩33.79 Billion | ₩29.81 Billion | ₩33.88 Billion |
| Income Tax Expense | — | — | — | ₩6.07 Billion | ₩7.42 Billion |
| Net Income | ₩13.60 Billion | ₩23.38 Billion | ₩29.77 Billion | ₩23.92 Billion | ₩26.66 Billion |
Whanin Pharm Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Whanin Pharm's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩478.89 Billion | ₩424.71 Billion | ₩401.23 Billion | ₩369.37 Billion | ₩353.19 Billion |
| Total Current Assets | ₩228.27 Billion | ₩201.30 Billion | ₩212.10 Billion | ₩197.42 Billion | ₩242.41 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩140.00 Million | ₩9.43 Billion | ₩33.09 Billion | ₩50.52 Billion | ₩81.91 Billion |
| Net Receivables | ₩61.88 Billion | ₩70.98 Billion | ₩74.53 Billion | ₩68.24 Billion | ₩61.88 Billion |
| Inventory | ₩96.32 Billion | ₩72.41 Billion | ₩54.06 Billion | ₩37.06 Billion | ₩32.75 Billion |
| Property, Plant & Equipment | — | — | — | ₩109.85 Billion | ₩46.87 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩57.88 Billion | ₩48.70 Billion | ₩43.02 Billion | ₩35.45 Billion | ₩35.96 Billion |
| Total Current Liabilities | ₩56.50 Billion | ₩42.38 Billion | ₩40.03 Billion | ₩31.75 Billion | ₩30.90 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | ₩421.01 Billion | ₩376.00 Billion | ₩358.21 Billion | ₩333.51 Billion | ₩316.94 Billion |
| Retained Earnings | ₩368.15 Billion | ₩358.86 Billion | ₩339.98 Billion | ₩314.79 Billion | ₩295.45 Billion |
Whanin Pharm Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Whanin Pharm generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩9.04 Billion | ₩20.69 Billion | ₩23.20 Billion | ₩16.85 Billion | ₩35.32 Billion |
| Capital Expenditures | ₩6.18 Billion | ₩29.38 Billion | ₩31.49 Billion | ₩33.65 Billion | ₩4.39 Billion |
| Free Cash Flow | ₩2.86 Billion | ₩-8.69 Billion | ₩-8.29 Billion | ₩-50.91 Billion | ₩30.56 Billion |
| Investing Cash Flow | — | — | — | ₩-38.94 Billion | ₩-2.12 Billion |
| Financing Cash Flow | — | — | — | ₩-5.13 Billion | ₩-5.19 Billion |
| Dividends Paid | ₩4.58 Billion | ₩4.58 Billion | ₩4.58 Billion | ₩4.58 Billion | ₩4.58 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩9.86 Billion | ₩8.47 Billion | ₩6.66 Billion | ₩4.85 Billion | ₩4.20 Billion |
| Change in Cash | ₩20.43 Billion | ₩-2.22 Billion | ₩8.59 Billion | ₩-27.28 Billion | ₩27.98 Billion |
Whanin Pharm Earnings History — EPS Actual vs. Analyst Estimates
Track Whanin Pharm's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 28, 2026 | — | — | — |
| Dec 31, 2025 | 113.85 | — | — |
| Oct 30, 2025 | 202.32 | — | — |
| Jul 28, 2025 | 208.80 | — | — |
| Apr 28, 2025 | 335.37 | — | — |
| Feb 17, 2025 | 234.77 | — | — |
| Nov 01, 2024 | 295.82 | — | — |
| Jul 29, 2024 | 406.69 | — | — |